Stereotactic ablative body radiotherapy (SABR) describes a radiotherapy technique where high doses of radiation are precisely delivered to an extra-cranial target within the body, using either a single fraction of radiotherapy or using multiple small number of fractions. SABR has now become the standard of care treatment for patients with early stage NSCLC for whom surgery is not appropriate. This systematic review considers the evidence supporting the use of SABR in early stage NSCLC, reported toxicity rates, the use of SABR in centrally located NSCLC, the use of SABR as salvage therapy following surgery or radiotherapy and future potential drug combinations with SABR.
|Number of pages||45|
|Journal||British Journal of Radiology|
|Early online date||25 Nov 2016|
|Publication status||Published - 17 Feb 2017|
Murray, P., Franks, K., & Hanna, G. (2017). A systematic review of outcomes following Stereotactic Ablative Radiotherapy in the treatment of early stage primary lung cancer. SABR for early stage NSCLC. British Journal of Radiology, 90(1071), 1. . https://doi.org/10.1259/bjr.20160732